Kevin Friedman, Kelonia president and CSO

Gene ther­a­py out­fit emerges from stealth with big am­bi­tions. First stop — CAR-T

There’s a new play­er in the gene ther­a­py space in Boston.

Backed by sci­ence out of Stan­ford and MIT, the small out­fit has big dreams, big am­bi­tions, and is cen­tered on try­ing to turn ex vi­vo gene ther­a­py in­to in vi­vo. How­ev­er, it’s start­ing with look­ing to re­de­fine CAR-T.

Kelo­nia Ther­a­peu­tics, backed by VCs such as Hori­zons Ven­tures and Ven­rock, of­fi­cial­ly launched Thurs­day af­ter be­ing in stealth for a lit­tle over a year, and has a bit of a cash stash thanks to $50 mil­lion from a Se­ries A. Pres­i­dent and CSO Kevin Fried­man told End­points News that the biotech has enough run­way to “progress us quite a ways to­ward the clin­ic” with­out giv­ing an ex­act time­frame.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA